Skip to main content

Drug Interactions between betibeglogene autotemcel and eflapegrastim

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

eflapegrastim betibeglogene autotemcel

Applies to: eflapegrastim and betibeglogene autotemcel

ADJUST DOSING INTERVAL: Granulocyte-colony stimulating factor (G-CSF) may interact with betibeglogene autotemcel. The mechanism has not been established. Hematopoietic stem cell (HSC) mobilization followed by apheresis to obtain CD34+ cells is required for betibeglogene autotemcel manufacturing. In two ongoing Phase 3 studies, G-CSF and plerixafor were used to mobilize stem cells prior to apheresis and were not recommended within 21 days after betibeglogene autotemcel infusion; however, 24% of patients in these studies received G-CSF within this 21-day period. No data are currently available for this interaction.

MANAGEMENT: According to the manufacturer, G-CSF is not recommended for 21 days after betibeglogene autotemcel infusion.

References

  1. (2022) "Product Information. Zynteglo (betibeglogene autotemcel)." bluebird bio

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer